Holen Sie sich die Stockscreener-App
2.04
3.77%
-0.08
Handel nachbörslich:
2.04
Schlusskurs vom Vortag:
$2.12
Offen:
$2.11
24-Stunden-Volumen:
312.34K
Relative Volume:
0.38
Marktkapitalisierung:
$87.01M
Einnahmen:
$55,200
Nettoeinkommen (Verlust:
$-21.24M
KGV:
-3.4664
EPS:
-0.5885
Netto-Cashflow:
$-19.37M
1W Leistung:
+15.25%
1M Leistung:
+19.30%
6M Leistung:
+12.71%
1J Leistung:
+17.92%
1-Tages-Spanne:
$2.03
$2.15
1-Wochen-Bereich:
$1.78
$2.37
52-Wochen-Spanne:
$1.53
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Firmenname
Gain Therapeutics Inc
Sektor
Branche
Telefon
(301) 500-1556
Adresse
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.04 | 90.43M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-08-14 | Fortgesetzt | Oppenheimer | Outperform |
| 2021-04-12 | Eingeleitet | BTIG Research | Buy |
| 2021-04-12 | Eingeleitet | Oppenheimer | Outperform |
Gain Therapeutics Inc Aktie (GANX) Neueste Nachrichten
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BTIG Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
BTIG Research Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX) - MarketBeat
Gain Therapeutics, Inc. Q2 2026: Net loss $4.7M, EPS $(0.11) — 10-Q Summary - TradingView
Gain Therapeutics (GANX) faces going-concern risk while advancing Parkinson’s drug - Stock Titan
Gain Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gain Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Gain Therapeutics Q2 Results: EPS Beats Estimates, Loss Narrows - scanx.trade
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall - TradingView
Gain Therapeutics 2Q Loss/Shr 11c >GANX - Moomoo
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update - Yahoo Finance
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Gain Therapeutics Inc (GANX) Stock News Today - TradingKey
Gain Therapeutics (GANX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Gain Therapeutics (GANX) Quietly Holds at $1.68 – Support Tightens Near Recent LowsRisk Parity Rebalance - dars.gov.et
Gain Therapeutics, Inc. Revenue Breakdown – NASDAQ:GANX - TradingView
GANX|Gain Therapeutics Inc|Price:1.855|Chg%:+0.105 - TradingKey
Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gain Therapeutics Inc (GANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gain Therapeutics Inc (GANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GANX|Gain Therapeutics Inc|Price:1.850|Chg%:-0.010 - TradingKey
Gain Therapeutics Inc (GANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gain Therapeutics Inc (GANX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Gain Therapeutics Inc (GANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GANX|Gain Therapeutics Inc|Price:1.750|Chg%:-0.070 - TradingKey
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Gain Therapeutics Extends Cash Runway Into 2027 Operations - The Globe and Mail
Form 4 Gain Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Gain Therapeutics (GANX) awards director 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards director 25,000 stock options - Stock Titan
Gain Therapeutics (GANX) director granted 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (NASDAQ: GANX) awards director 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards director 25,000 options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards 25,000 options to director at $1.68 strike - Stock Titan
Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Terenzio Ignoni as COO - Moomoo
Gain Therapeutics plans phase 2 Parkinson’s study in Q3 2026 By Investing.com - Investing.com South Africa
Gain Therapeutics says cash runway extends into Q2 2027 amid Phase 2 start plans - TradingView
Gain Therapeutics plans phase 2 Parkinson’s study in Q3 2026 - Investing.com
Gain Therapeutics (NASDAQ: GANX) sees cash funding into Q2 2027 - Stock Titan
Gain Therapeutics advances Parkinson's drug rex... - Pluang
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update - marketscreener.com
Gain Therapeutics Reports 81% Biomarker Drop in Some Patients - Stock Titan
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Gain Therapeutics (GANX) Q1 2026 earnings summary - Quartr
Gain Therapeutics (GANX) The 38th Annual Roth Conference Summary - Quartr
Gain Therapeutics (GANX) Proxy filing Summary - Quartr
Gain Therapeutics (GANX) Q4 2025 earnings summary - Quartr
Finanzdaten der Gain Therapeutics Inc-Aktie (GANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.20%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):